Scientists just took a big, “very positive” step towards developing what could be the first ‘universal cancer vaccine’.
The results from early trials in humans, along with research in mice, have just been published, and they suggest that the new technique could be used to activate patients’ immune systems against any type of tumour, no matter where it is in the body.
Unlike the vaccines we’re familiar with, this potential vaccine would be given to patients who already have cancer, rather than those at risk of getting it. It basically works by shooting tiny ‘darts’ containing pieces of RNA extracted from the patient’s cancer cells at the body’s own immune system, convincing them to launch an all-out attack on any tumours they come across.
By just changing the RNA inside those darts, the team can, in theory, mobilise the immune system against any kind of cancer. “[Such] vaccines are fast and inexpensive to produce, and virtually any tumour antigen can be encoded by RNA,” the team, led by researchers at Johannes Gutenberg University of Mainz in Germany,reports in Nature.
“Thus, the nanoparticulate RNA immunotherapy approach introduced here may be regarded as a universally applicable novel vaccine class for cancer immunotherapy.”